Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Nov 08, 2024 6:51pm
89 Views
Post# 36304165

RE:RE:RE:RE:RE:RE:Antibody-Drug Conjugate (ADC) developments

RE:RE:RE:RE:RE:RE:Antibody-Drug Conjugate (ADC) developments

China's investigation has resulted in a series of charges against AZ staffers and convictions with prison sentences of more than 10 years in some cases, according to local media reports.

Another line of enquiry, which first emerged earlier this year, involves data privacy breaches and the import of unlicensed medicines. Now, it has been reported by analysts that the illegal imports could have involved cancer treatments Enhertu (trastuzumab deruxtecan), Imfinzi (durvalumab), or Imjudo (tremelimumab).

AZ is not prepared to comment on the nature of the investigations, other than to confirm they are ongoing, and has reiterated its position that it will "fully cooperate with the Chinese authorities."

https://pharmaphorum.com/news/az-confirms-china-president-has-been-detained

 

<< Previous
Bullboard Posts
Next >>